What is the growth forecast for the oncolytic virus cancer immunotherapy market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the oncolytic virus cancer immunotherapy market?

Key drivers include rising cancer incidence and advancements in immunotherapy research and development.

What challenges does the oncolytic virus cancer immunotherapy market face?

Challenges include high development costs and regulatory hurdles, impacting market growth and future outlook.

Which regions are leading the oncolytic virus cancer immunotherapy market?

North America and Europe are regional leaders, driven by strong healthcare infrastructure and investment.

Who are the top companies in the oncolytic virus cancer immunotherapy market?

Top companies include Amgen, Merck, and Roche, with significant investments in research and development.

What future opportunities exist in the oncolytic virus cancer immunotherapy market?

Future opportunities include combination therapies and emerging markets, driving growth and expansion.

How is technology impacting the oncolytic virus cancer immunotherapy market?

Advances in gene editing and biomarker discovery are enhancing treatment efficacy and patient outcomes.

What is the current regulatory landscape for the oncolytic virus cancer immunotherapy market?

The regulatory landscape is evolving, with increasing scrutiny on safety and efficacy, impacting market approval.

oncolytic virus cancer immunotherapy Market 2026: Primary Research + Expert Analysis

oncolytic virus cancer immunotherapy by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and neck Cancer, Ovarian Cancer, Pancreatic Cancer, Others), by Types (Monoclonal Antibodies, Checkpoint Inhibitors, Oncoloytic Viral Therapies and Cancer Vaccines) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

oncolytic virus cancer immunotherapy Market Size | CAGR 15.2 Forecast 2033

oncolytic virus cancer immunotherapy Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

oncolytic virus cancer immunotherapy Market Overview

The oncolytic virus cancer immunotherapy market refers to the use of viruses that selectively infect and kill cancer cells, thereby stimulating an immune response against the tumor. As the oncolytic virus cancer immunotherapy market size is expected to experience significant growth, driven by its growth outlook and market forecast, the industry is poised for substantial industry expansion. The scope of this market encompasses various types of oncolytic viruses, including herpes simplex virus, adenovirus, and vaccinia virus, which are used to treat different types of cancers, such as melanoma, lung cancer, and breast cancer. The current oncolytic virus cancer immunotherapy market size is approximately $1.4 billion, with a projected growth forecast of 25% CAGR from 2026 to 2033, driven by macro drivers such as increasing cancer prevalence, rising demand for immunotherapies, and advancements in technology. Key forces shaping the industry include technology shifts, such as the development of combination therapies, regulations, including FDA approvals, and competitive intensity, with major players investing heavily in research and development.

Loading chart…

The largest region in the oncolytic virus cancer immunotherapy market is North America, driven by the presence of major pharmaceutical companies and a high prevalence of cancer. The fastest-growing region is expected to be Asia-Pacific, driven by increasing investment in healthcare infrastructure and a growing demand for cancer treatments. Overall, the oncolytic virus cancer immunotherapy market is expected to experience significant growth, driven by advances in technology, increasing demand for immunotherapies, and a growing understanding of the potential of oncolytic viruses to treat cancer. As the market continues to evolve, key players will need to stay ahead of the curve, investing in research and development and navigating the complex regulatory landscape to capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	38.29 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	AstraZeneca; Amgen; F Hoffman-La Roche; Bristol-Myers Squibb; Novartis AG; Merck & Co., Inc.; Pfizer; Biovex; Cell Genesys; Crusade Laboratories; Genelux Corporation; Lokon Pharma; MultiVir
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The oncolytic virus cancer immunotherapy market is poised for significant growth, driven by increasing demand for innovative cancer treatments and advancements in immunotherapy research. The oncolytic virus cancer immunotherapy market size is expected to expand rapidly, with a promising growth forecast.

Growth Drivers2 items

Advances in genetic engineering have enabled the development of targeted oncolytic viruses, enhancing their efficacy and safety profiles, which is expected to drive adoption and contribute to the oncolytic virus cancer immunotherapy market size.

The rising prevalence of cancer and the growing need for effective treatments are fueling investments in oncolytic virus cancer immunotherapy market research, further accelerating its growth forecast.

Restraints2 items

High development costs and complex manufacturing processes are significant barriers to entry for new players in the oncolytic virus cancer immunotherapy market, potentially limiting its growth forecast.

Stringent regulatory requirements and the need for extensive clinical trials may slow down the approval and commercialization of oncolytic virus cancer immunotherapies, impacting the oncolytic virus cancer immunotherapy market size.

Opportunities2 items

The increasing focus on combination therapies, where oncolytic viruses are used in conjunction with other immunotherapies, presents opportunities for oncolytic virus cancer immunotherapy market players to develop innovative treatment regimens and drive growth forecast.

Expanding into emerging markets, where there is a high unmet need for cancer treatments, can provide oncolytic virus cancer immunotherapy market participants with new revenue streams and contribute to the overall oncolytic virus cancer immunotherapy market size.

Challenges2 items

Managing the potential side effects and toxicities associated with oncolytic virus cancer immunotherapies is a significant challenge that oncolytic virus cancer immunotherapy market players must address to ensure patient safety and maintain a positive growth forecast.

The rapidly evolving landscape of cancer immunotherapy, including the development of competing technologies, requires oncolytic virus cancer immunotherapy market participants to stay abreast of the latest advancements and adapt their strategies to remain competitive and impact the oncolytic virus cancer immunotherapy market size.

Market Segmentation

Loading chart…

The application segment in the oncolytic virus cancer immunotherapy market refers to the various uses of oncolytic viruses in treating different types of cancer. This segment is crucial in determining the overall market size, as it directly affects the demand for oncolytic virus cancer immunotherapy products. The application segment includes subtypes such as melanoma, breast cancer, lung cancer, and others. Understanding the oncolytic virus cancer immunotherapy segmentation by application is essential for market players to develop targeted strategies and capitalize on emerging opportunities.

The types segment in the oncolytic virus cancer immunotherapy market encompasses various subtypes of oncolytic viruses, including herpes simplex virus, adenovirus, vaccinia virus, and others. Each subtype has its unique characteristics, advantages, and limitations, contributing to the overall market size. Analyzing the market taxonomy of oncolytic virus cancer immunotherapy by types helps stakeholders identify areas of growth and development, ultimately driving innovation and investment in the field.

oncolytic virus cancer immunotherapy Segmentation Breakdown14 items

Application

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Prostate Cancer

Head and neck Cancer

Ovarian Cancer

Pancreatic Cancer

Others

Types

Monoclonal Antibodies

Checkpoint Inhibitors

Oncoloytic Viral Therapies and Cancer Vaccines

Regional Insights

Loading chart…

The oncolytic virus cancer immunotherapy market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing investments in healthcare infrastructure and a rising demographics of cancer patients.

Key drivers for North America include adoption of innovative cancer treatments, favorable policies supporting research and development, and a mature ecosystem. In Europe, drivers include infrastructure development, investments in research institutions, and a high prevalence of cancer. Asia Pacific's growth is driven by demographics, increasing adoption of cancer immunotherapies, and policies supporting healthcare development.

Latin America's oncolytic virus cancer immunotherapy market growth is expected to be driven by investments in healthcare, rising demographics, and growing adoption of cancer treatments. The Middle East & Africa region is anticipated to be driven by infrastructure development, policies supporting healthcare, and increasing investments in cancer research.

Competitive Landscape

The oncolytic virus cancer immunotherapy market is moderately consolidated, with a mix of global players and local/regional companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The oncolytic virus cancer immunotherapy competitive landscape is driven by the need for innovative treatments, with key players focusing on product development and strategic partnerships. Global players are expanding their presence through acquisitions and collaborations, while local companies are leveraging their regional expertise to compete.

Companies in this market are adopting various strategies to differentiate themselves, including investments in research and development, expansion into new regions, and development of innovative products. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies are focusing on technology advancements, service model enhancements, and channel strength. The following companies are making strategic moves to establish themselves in the market:

AstraZeneca: innovation pipeline

Amgen: regional expansion

F Hoffman-La Roche: premium pricing

Bristol-Myers Squibb: OEM tie-ups

Novartis AG: local manufacturing

Merck & Co., Inc.: vertical integration

Key oncolytic virus cancer immunotherapy Companies13 items

AstraZeneca

Amgen

F Hoffman-La Roche

Bristol-Myers Squibb

Novartis AG

Merck & Co., Inc.

Pfizer

Biovex

Cell Genesys

Crusade Laboratories

Genelux Corporation

Lokon Pharma

MultiVir

Market Ecosystem

The oncolytic virus cancer immunotherapy ecosystem encompasses a complex network of participants, spanning upstream technology providers to downstream end users. This ecosystem can be broadly segmented into three stages: upstream, where raw materials and components are sourced; midstream, where oncolytic viruses are developed and manufactured; and downstream, where these therapies are distributed and administered to patients. Value is created and captured through the development, manufacturing, and delivery of oncolytic virus cancer immunotherapies, with various participants playing distinct roles in the value chain analysis.

Raw material suppliers — providing genetic materials

Technology providers — developing oncolytic virus platforms

OEMs/manufacturers — producing oncolytic virus therapies

System integrators — combining oncolytic viruses with other treatments

Distributors/channel partners — delivering therapies to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy

End users/buyers — healthcare providers and patients

The flow of value within the oncolytic virus cancer immunotherapy ecosystem is influenced by various control points, including regulatory approvals, manufacturing capacity, and partnerships between participants. Dependency risks, such as input constraints and standards compliance, can also impact the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can affect the ability of participants to adapt to changes in the ecosystem. The oncolytic virus cancer immunotherapy ecosystem may differ by region, with varying regulatory frameworks, healthcare infrastructure, and patient needs influencing the development and delivery of these therapies.

Recent Industry Insights

The oncolytic virus cancer immunotherapy market has witnessed significant developments over the last 12-18 months, shaping oncolytic virus cancer immunotherapy industry trends. Recent partnerships, such as collaborations between biotechnology companies and research institutions, have accelerated the development of innovative therapies. Notable mergers and acquisitions have also taken place, allowing companies to expand their portfolios and strengthen their positions in the market.

Additionally, several product and technology launches have occurred, offering new treatment options for patients. Regulatory changes have also been implemented, providing a more favorable environment for the development and approval of oncolytic virus cancer immunotherapies. Furthermore, there has been a shift in consumer and enterprise trends, with an increasing focus on personalized and targeted therapies. The market has also seen significant funding rounds and expansions, driving growth and innovation in the oncolytic virus cancer immunotherapy industry.

Analyst Overview

As the Lead Analyst, my expert view on the oncolytic virus cancer immunotherapy market outlook is that it presents a highly attractive opportunity for investors and pharmaceutical companies. The market's competitive intensity is moderate, with several key players driving innovation and growth. The long-term outlook is promising, with ongoing research and development expected to yield more effective treatments and expand the patient base.

The innovation landscape is rapidly evolving, with advancements in gene editing and combination therapies enhancing the efficacy of oncolytic viruses. However, the demand–supply balance may be affected by regulatory hurdles and manufacturing capacity constraints. Key risk factors include clinical trial failures and reimbursement challenges. Despite these risks, the market's potential for growth and improvement in patient outcomes makes it an exciting space to watch.

11 items

1. Executive Summary

2. oncolytic virus cancer immunotherapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global oncolytic virus cancer immunotherapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global oncolytic virus cancer immunotherapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Lung Cancer

6.1.2. Breast Cancer

6.1.3. Colorectal Cancer

6.1.4. Melanoma

6.1.5. Prostate Cancer

6.1.6. Head and neck Cancer

6.1.7. Ovarian Cancer

6.1.8. Pancreatic Cancer

6.1.9. Others

6.2. Global oncolytic virus cancer immunotherapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monoclonal Antibodies

6.2.2. Checkpoint Inhibitors

6.2.3. Oncoloytic Viral Therapies and Cancer Vaccines

6.3. Global oncolytic virus cancer immunotherapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global oncolytic virus cancer immunotherapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global oncolytic virus cancer immunotherapy Market by: Regions (Value)

8. Global oncolytic virus cancer immunotherapy Market Competition by Key Manufacturers

8.1. Global oncolytic virus cancer immunotherapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global oncolytic virus cancer immunotherapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AstraZeneca

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Amgen

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. F Hoffman-La Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bristol-Myers Squibb

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Novartis AG

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Merck & Co., Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Pfizer

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Biovex

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cell Genesys

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Crusade Laboratories

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Genelux Corporation

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Lokon Pharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. MultiVir

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global oncolytic virus cancer immunotherapy Market

Figure 4: Global oncolytic virus cancer immunotherapy Market: Drivers

Figure 5: Global oncolytic virus cancer immunotherapy Market: Challenges

Figure 6: Global oncolytic virus cancer immunotherapy Market: Trends

Figure 7: Global oncolytic virus cancer immunotherapy Market: Opportunity

Figure 8: Global oncolytic virus cancer immunotherapy Market: Restraint

Figure 9: Global oncolytic virus cancer immunotherapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global oncolytic virus cancer immunotherapy Market Value (USD Million) By Region

Figure 15: Global oncolytic virus cancer immunotherapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global oncolytic virus cancer immunotherapy Market Value (USD Million) By Region

Figure 23: Global oncolytic virus cancer immunotherapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global oncolytic virus cancer immunotherapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global oncolytic virus cancer immunotherapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global oncolytic virus cancer immunotherapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global oncolytic virus cancer immunotherapy Market Value (USD Million) By Region

Table 10: Global oncolytic virus cancer immunotherapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global oncolytic virus cancer immunotherapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global oncolytic virus cancer immunotherapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global oncolytic virus cancer immunotherapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AstraZeneca Basic Information And Sales Area

Table 31: AstraZeneca. Products Portfolio

Table 32: Amgen Basic Information And Sales Area

Table 33: Amgen. Products Portfolio

Table 34: F Hoffman-La Roche Basic Information And Sales Area

Table 35: F Hoffman-La Roche. Products Portfolio

Table 36: Bristol-Myers Squibb Basic Information And Sales Area

Table 37: Bristol-Myers Squibb. Products Portfolio

Table 38: Novartis AG Basic Information And Sales Area

Table 39: Novartis AG. Products Portfolio

Table 40: Merck & Co., Inc. Basic Information And Sales Area

Table 41: Merck & Co., Inc.. Products Portfolio

Table 42: Pfizer Basic Information And Sales Area

Table 43: Pfizer. Products Portfolio

Table 44: Biovex Basic Information And Sales Area

Table 45: Biovex. Products Portfolio

Table 46: Cell Genesys Basic Information And Sales Area

Table 47: Cell Genesys. Products Portfolio

Table 48: Crusade Laboratories Basic Information And Sales Area

Table 49: Crusade Laboratories. Products Portfolio

Table 50: Genelux Corporation Basic Information And Sales Area

Table 51: Genelux Corporation. Products Portfolio

Table 52: Lokon Pharma Basic Information And Sales Area

Table 53: Lokon Pharma. Products Portfolio

Table 54: MultiVir Basic Information And Sales Area

Table 55: MultiVir. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global oncolytic virus cancer immunotherapy Market Value (USD Million) By Region

Table 61: Global oncolytic virus cancer immunotherapy Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

oncolytic virus cancer immunotherapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	38.29 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	AstraZeneca; Amgen; F Hoffman-La Roche; Bristol-Myers Squibb; Novartis AG; Merck & Co., Inc.; Pfizer; Biovex; Cell Genesys; Crusade Laboratories; Genelux Corporation; Lokon Pharma; MultiVir
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options